SBA 7(a) and 504 for Independent pharmacy
SBA 7(a) and 504 for independent pharmacy
Direct answer
SBA 7(a) finances the acquisition of an independent pharmacy or its prescription files up to $5,000,000, priced from prime plus a spread, while SBA 504 finances owner-occupied pharmacy real estate at a reduced equity injection. Practition Finance explains how PBM contract terms are read in underwriting and, by state, refers the request to funding partners.
As of October 2026
An independent pharmacy acquisition is priced on script count and file retention, and financed differently depending on whether the buyer is purchasing the whole business or just the prescription files from a closing location. SBA 7(a) reaches $5,000,000 and is structured to finance either path, along with the working capital a buyer needs to bridge the gap between paying the wholesaler on its terms and collecting reimbursement from the payer mix behind those scripts.
Reimbursement mechanics separate pharmacy from most other healthcare acquisitions an SBA lender underwrites. Direct and indirect remuneration fees assessed after the point of sale can reduce the gross margin a buyer expected when reviewing trailing financials, and PBM contract terms transfer to a new owner largely as written, with little room to renegotiate before closing. A lender reading a pharmacy acquisition checks gross margin after DIR fees, not gross margin before them.
Wholesaler terms add a working capital dimension that shows up immediately after closing. A pharmacy typically pays its primary wholesaler on short terms while waiting considerably longer for PBM reimbursement to land, and that spread has to be financed by something, whether that is cash in the deal, a line of credit, or working capital built into the acquisition structure itself. Practition Finance explains how SBA lenders size that gap and, by state, refers the request to funding partners.
Why this program fits your situation
SBA 7(a) and 504 fit an independent pharmacy at four points where the acquisition, working capital, or real estate need exceeds conventional bank terms
Acquisition of the business or the prescription files
SBA 7(a) finances both structures: buying the full pharmacy business, including its lease, staff, and inventory, or buying only the prescription files from a location that is closing. File-only acquisitions are priced and financed differently because there is no physical business or staff transferring, just the script count and the patient relationships behind it. A lender underwriting a file acquisition focuses almost entirely on retention rate after transfer, since that is the only asset actually changing hands.
Inventory line bridging wholesaler terms and reimbursement timing
A pharmacy pays its primary wholesaler on terms set by that relationship, often shorter than the time it takes PBM reimbursement to arrive for the scripts filled with that inventory. SBA 7(a) working capital, financed alongside an acquisition or as a standalone facility, covers that spread so the pharmacy is not managing wholesaler payment timing against its own operating cash every month. This is a recurring structural gap in the business, not a one-time event, and the financing should be sized accordingly.
Owner-occupied real estate through SBA 504
A pharmacy that owns the building it operates from finances that real estate through SBA 504's paired structure: a bank note for the majority and a debenture that lowers the equity injection required for an established pharmacy. Combining the business acquisition through 7(a) and the real estate through 504 in one project lets a buyer size each piece against the collateral and cash flow that actually supports it, rather than stretching one loan across both.
Buying out a retiring pharmacist owner with continuity risk
An independent pharmacy sale often hinges on whether the community keeps using the pharmacy after the owner who built the relationships steps away, which is a script retention question more than a real estate or equipment question. SBA 7(a) finances that acquisition against the trailing script count and PBM contract terms, and lenders in this category commonly want a transition period with the outgoing owner built into the deal to protect the retention rate the financing is underwritten against.
Directional terms for a file like yours
What the numbers mean for an independent pharmacy acquisition
| What it measures | Market range | Confidence | How to read it |
|---|---|---|---|
| SBA 7(a) maximum | $5,000,000, guaranty 85% to $150,000 and 75% above6 | VerifiedAugust 2026 | The $5,000,000 ceiling and guaranty structure covers a pharmacy acquisition, its inventory line, and working capital together in most independent pharmacy deals. |
| SBA 7(a) fees | At statutory maximums (Notice 5000-872051)7 | VerifiedAugust 2026 | Fee levels for the current fiscal year affect the total cost of a pharmacy acquisition loan and should be built into the buyer's cash needed at closing. |
| SBA 504 equity injection | 10% established, 15% startup or special-use8 | VerifiedAugust 2026 | The established-operation injection rate in the table above applies to an operating pharmacy buying its real estate, lowering the cash a buyer needs to bring to the property piece of a combined deal. |
| Base lending rate | 6.75%9 | VerifiedAugust 2026 | SBA 7(a) pricing floats from prime plus a spread, so the prime rate is the starting point for estimating the acquisition loan's payment. |
| Debt service coverage floor | 1.15x minimum on SBA 7(a) credit, measured on the borrower's operating cash flow10 | DirectionalAugust 2026 | The 1.20 to 1.25 minimum is checked against the pharmacy's margin after DIR fees, not its gross margin before them, when a lender finalizes the loan amount. |
These are ranges the market publishes, current as of the date beside each one. None of it is a quote, an offer, or an indication of terms.
The 3 things that cost owners here
Underwriting the deal on gross margin before DIR fees
A buyer who reviews a pharmacy's trailing financials and calculates margin before direct and indirect remuneration fees are applied is working from a number the pharmacy has never actually kept. DIR fees assessed after the point of sale reduce realized margin, sometimes significantly, and a lender underwriting the acquisition will adjust for this even if the buyer's initial analysis did not. Requesting margin figures net of DIR fees from the seller before submitting the loan request avoids a mid-underwriting correction that can change the loan amount.
Assuming PBM contracts are negotiable at closing
A buyer entering a pharmacy acquisition sometimes plans to renegotiate unfavorable PBM reimbursement terms shortly after taking over, treating the current contracts as a temporary condition. PBM contracts are set largely outside the pharmacy's control and rarely change meaningfully on a new owner's timeline. Underwriting and pricing the deal against the reimbursement terms as they exist at closing, not as the buyer hopes they will become, keeps the debt service projection realistic.
Skipping a working capital line for wholesaler terms
A buyer who finances only the purchase price and the real estate, without a dedicated inventory or working capital line, is betting that day-one cash flow covers the spread between wholesaler payment terms and PBM reimbursement timing. That spread is a structural feature of the business, not a startup cost that disappears after the first quarter, and a pharmacy without a facility to cover it can find itself managing vendor terms adversarially within months of closing.
Run your numbers
SBA payment calculator
Model the payment on an SBA 7(a) pharmacy acquisition loan against the pharmacy's margin after DIR fees
Open the calculatorWhat owners ask about this combination
01Can SBA 7(a) finance a prescription file acquisition instead of a full business purchase?
Yes, SBA 7(a) finances file-only acquisitions, where a buyer purchases the prescription files and patient relationships from a closing pharmacy rather than the physical business. Underwriting for this structure focuses heavily on the retention rate expected after the transfer, since the files are the primary asset. Practition Finance explains how lenders size a file acquisition differently than a full business purchase before a buyer submits the request.
02How do DIR fees affect an SBA pharmacy loan?
Direct and indirect remuneration fees reduce a pharmacy's realized margin below what a surface-level review of gross revenue would suggest, and SBA lenders underwrite pharmacy acquisitions using margin figures net of these fees. A buyer who submits a request based on pre-DIR margin should expect the lender to recalculate and potentially adjust the loan amount. Underwriters commonly expect DIR-adjusted financials before the file goes to underwriting.
03Does SBA 504 work for a pharmacy buying its own building?
SBA 504 fits an established pharmacy purchasing owner-occupied real estate, pairing a bank note with a debenture at a reduced equity injection for an established operation. It is commonly combined with an SBA 7(a) loan financing the pharmacy business acquisition itself, letting a buyer size the real estate and the business purchase separately. Practition Finance explains how the two programs are structured together in a combined pharmacy transaction.
04What does an SBA lender look at first in a pharmacy deal?
Lenders start with script count and file retention history, since that determines whether the revenue base survives the ownership change, then move to gross margin after DIR fees and wholesaler terms against reimbursement timing. Payer mix and PBM contract exposure round out the underwriting picture. A pharmacy-focused underwriter expects this documentation in a set order.
05How long does SBA financing take to close on a pharmacy acquisition?
The market range for SBA-backed acquisitions is 45 to 120 days from application to close, and pharmacy deals often land toward the middle of that range once DIR-adjusted financials and wholesaler agreements are in order. A file-only acquisition with a tight closing deadline in the purchase agreement should be flagged to the lender early. Buyers commonly sequence the SBA timeline against the deal's contractual deadlines.
Sources
- 1SBA 7(a) loan program overview
- 2SBA 504 loan program overview
- 3National Community Pharmacists Association
- 4CMS Medicare Part D resources
- 5Federal Reserve Wall Street Journal prime rate history
- 6SBA-derived calculators
- 7NAGGL
- 8Janover Pro
- 9Lendio, sbaloanindex.com
- 10U.S. Small Business Administration, SOP 50 10
Start a Fit Check to see how SBA 7(a) and 504 line up with your independent pharmacy acquisition